Loading…
Employees: 2,843
Size Guangxi Wuzhou Zhongheng (600252.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.03B, the 2248th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥2.19 on 6 Nov 2026.
Performance Over six months the shares fell 11.0%, against -13.0% for the median peer and -16.4% for the China market (cap-weighted) — 10th highest of 20 in its peer set.
Growth Revenue fell 43.1% over the last twelve months (peer median +7.4%); the operating margin is -41.8% (peer median 8.1%).
Valuation It trades at 5.0× enterprise value to sales against a peer median of 3.0× (5th most expensive of 19).
Price implies For today's price to make sense, revenue must grow about 12% a year for seven years (Req g). Recent delivered growth is -14%, so the hurdle is +26 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 10.4 points below its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.30B | CN¥1.74B | CN¥2.09B | CN¥3.07B | CN¥2.69B |
| Revenue growth | — | -17% | -32% | +14% | — |
| Gross profit | CN¥671M | CN¥660M | CN¥863M | CN¥1.77B | CN¥1.48B |
| EBITDA | n/a | -CN¥178M | -CN¥108M | CN¥120M | CN¥135M |
| Net income | -CN¥419M | -CN¥357M | -CN¥377M | CN¥84.3M | CN¥79.0M |
| Free cash flow | CN¥153M | -CN¥17.8M | CN¥389M | CN¥317M | -CN¥318M |
| Capital expenditure | CN¥46.1M | CN¥101M | CN¥199M | CN¥167M | CN¥202M |
| Total debt | CN¥763M | CN¥1.77B | CN¥1.98B | CN¥1.79B | CN¥1.97B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600252.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.9% | -3.4% | 6th highest of 21 |
| 6-month return | -11.0% | -13.0% | 10th highest of 20 |
| Distance from 52-week high | -29.4% | -32.2% | 10th highest of 21 |
| Revenue growth (TTM) | -43.1% | +7.4% | 2nd lowest of 19 |
| Operating margin | -41.8% | 8.1% | 3rd lowest of 19 |
| EV / Sales | 5.0× | 3.0× | 5th most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | 11.9% | 3.4% | 4th most demanding of 14 |
| Growth delivered (Del g) | -13.7% | +3.5% | lowest of 14 |
| Hurdle (Req g minus delivered) | +25.6 pp | +1.5 pp | 2nd most demanding of 14 |
| ROIC minus cost of capital | -10.4 pp | -0.7 pp | lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Guangxi Wuzhou Zhongheng 600252.SS | China | $1.03B | -11% | -43% | -42% | 5.0× | 11.9% | -13.7% |
| Symbiotec Pharmalab SYMBIOTEC.NS | India | $1.03B | n/a | n/a | n/a | n/a | n/a | n/a |
| SAWAI 4887.T | Japan | $1.03B | -22% | +11% | 9% | 1.3× | n/a | n/a |
| Towa Pharmaceutical 4553.T | Japan | $1.03B | -16% | +7% | 9% | 1.2× | 1.5% | +12.1% |
| Oscotec 039200.KS | South Korea | $1.02B | -30% | +233% | 62% | 8.3× | -9.5% | +18.1% |
| Sunflower Pharmaceutical 002737.SZ | China | $1.04B | -13% | +31% | -7% | 1.8× | -6.4% | -7.7% |
| Jiangsu Kanion Pharmaceutical 600557.SS | China | $1.05B | -6% | +8% | 7% | 1.5× | 3.4% | +1.8% |
| Harrow HROW | United States | $1.01B | -30% | +21% | 2% | 4.4× | 51.8% | +41.0% |
| KPC Pharmaceuticals 600422.SS | China | $1.00B | -7% | -41% | -10% | 1.9× | n/a | n/a |
| Harbin Gloria Pharmaceuticals 002437.SZ | China | $999M | -15% | -16% | 13% | 3.0× | 8.8% | -6.9% |
| Renhe Pharmacy 000650.SZ | China | $1.06B | -10% | -7% | 14% | 1.0× | -9.4% | -7.0% |
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $1.06B | -18% | -27% | -19% | 3.0× | n/a | n/a |
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $1.07B | -47% | -55% | -457% | 68.9× | n/a | n/a |
| Savara SVRA | United States | $992M | -8% | n/a | n/a | n/a | n/a | n/a |
| SSY 2005.HK | Hong Kong | $990M | +10% | -4% | 12% | 2.3× | 2.1% | -0.5% |
| Basilea Pharmaceutica BSLN.SW | Switzerland | $1.07B | +27% | +5% | 24% | 3.2× | -5.7% | +12.7% |
| Viyash Scientific VIYASH.NS | India | $1.07B | +3% | +96% | 13% | 3.2× | 38.6% | +20.4% |
| CStone Pharmaceuticals 2616.HK | Hong Kong | $1.07B | -38% | +117% | -89% | 14.8× | n/a | n/a |
| Sichuan Huiyu Pharmaceutical 688553.SS | China | $1.07B | -15% | +8% | 7% | 4.7× | 34.1% | -6.0% |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.08B | -2% | +27% | 4% | 2.4× | 5.0% | +3.5% |
| Zhejiang Garden Biopharmaceutical 300401.SZ | China | $983M | -7% | +2% | 24% | 5.5× | 10.2% | +13.4% |